These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20122673)

  • 1. Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin).
    Papi S; Martano L; Garaboldi L; Rossi A; Cremonesi M; Grana CM; Paolucci D; Sansovini M; Paganelli G; Chinol M
    Nucl Med Biol; 2010 Jan; 37(1):85-93. PubMed ID: 20122673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation dose measurements for personnel performing 90Y-ibritumomab tiuxetan administration: a comparison between two injection methods for dose reduction.
    Law M; Liu R; Ng S; Luk MY; Leung TW; Au GK
    Br J Radiol; 2009 Jun; 82(978):491-6. PubMed ID: 19188242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occupational radiation exposure of medical staff performing ⁹⁰Y-loaded microsphere radioembolization.
    Laffont S; Rolland Y; Ardisson V; Edeline J; Pracht M; Le Sourd S; Rohou T; Lenoir L; Lepareur N; Garin E
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):824-831. PubMed ID: 26686335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin dose saving of the staff in 90Y/177Lu peptide receptor radionuclide therapy with the automatic dose dispenser.
    Fioroni F; Grassi E; Giorgia C; Sara R; Piccagli V; Filice A; Mostacci D; Versari A; Iori M
    Nucl Med Commun; 2016 Oct; 37(10):1046-52. PubMed ID: 27218429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety.
    Cremonesi M; Ferrari M; Paganelli G; Rossi A; Chinol M; Bartolomei M; Prisco G; Tosi G
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1321-7. PubMed ID: 16832636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extremity Exposure with
    Nyathi M; Moeng TM; Maboe DPA
    Curr Radiopharm; 2021; 14(1):57-63. PubMed ID: 32720609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of three cold kit reconstitution techniques for the reduction of hand radiation dose.
    Bogsrud TV; Herold TJ; Mahoney DW; Hung JC
    Nucl Med Commun; 1999 Aug; 20(8):761-7. PubMed ID: 10451885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finger doses for staff handling radiopharmaceuticals in nuclear medicine.
    Pant GS; Sharma SK; Rath GK
    J Nucl Med Technol; 2006 Sep; 34(3):169-73. PubMed ID: 16951286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radiation exposure in (90)Y-Zevalin therapy: results of a prospective multicentre trial].
    Geworski L; Zöphel K; Rimpler A; Barth I; Lassmann M; Sandrock D; Zander A; Halm T; Hänscheid H; Hofmann M; Reiners C; Munz DL
    Nuklearmedizin; 2006; 45(2):82-6; quiz N15-6. PubMed ID: 16547569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [External exposure of hot cell operators in nuclear medicine].
    Sichirollo AE; Bombardieri E; Cortona G; Marchesini R
    Radiol Med; 1998 Dec; 96(6):612-7. PubMed ID: 10189927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation emission dose from patients administered 90Y-labelled radiopharmaceuticals: comparison of experimental measurements versus Monte Carlo simulation.
    Meo SL; Cicoria G; Montini G; Bergamini C; Campanella F; Pancaldi D; Panebianco AS; Rubello D; Marengo M
    Nucl Med Commun; 2008 Dec; 29(12):1100-5. PubMed ID: 18987532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of extremity dose in the radiopharmacy.
    Mackenzie A
    Nucl Med Commun; 1997 Jun; 18(6):578-81. PubMed ID: 9259532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
    Conti PS; White C; Pieslor P; Molina A; Aussie J; Foster P
    J Nucl Med; 2005 Nov; 46(11):1812-8. PubMed ID: 16269594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
    Chiesa C; Botta F; Di Betta E; Coliva A; Maccauro M; Aliberti G; Bavusi S; Devizzi L; Guidetti A; Seregni E; Gianni AM; Bombardieri E
    Cancer Biother Radiopharm; 2007 Feb; 22(1):113-20. PubMed ID: 17627419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control.
    Urbano N; Modoni S
    Nucl Med Commun; 2007 Dec; 28(12):943-50. PubMed ID: 18090222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extremity dosimetry for radiation workers handling unsealed radionuclides in nuclear medicine departments in India.
    Tandon P; Venkatesh M; Bhatt BC
    Health Phys; 2007 Feb; 92(2):112-8. PubMed ID: 17220712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.
    Tran L; Baars JW; Maessen HJ; Hoefnagel CA; Beijnen JH; Huitema AD
    Cancer Biother Radiopharm; 2009 Feb; 24(1):103-10. PubMed ID: 19243252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of doses to the hands during dispensing of radiopharmaceuticals.
    Dhanse S; Martin CJ; Hilditch TE; Elliott AT
    Nucl Med Commun; 2000 Jun; 21(6):511-9. PubMed ID: 10894559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.